{
  "docId": "019de076-bff7-7739-a1e4-b124be2aa055",
  "docSlug": "9628ad2ef05910b50c9df1eb370993a9",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 15,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a grid layout to present four key performance pillars and a sidebar for real-world evidence.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-bff7-7739-a1e4-b124be2aa055/11",
  "deckHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055",
  "deckJsonHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055.json",
  "deckAnchorHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "MSE 45%, QoL, Steroid tapering, 4,000 patient years of safety follow-up",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcf8cfb5-83c8-459f-86d2-b87e7195230d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "metric",
      "text": ">2,300* Prescribers in the US",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "577e127a-1c9c-4114-9b6d-dc41181d73f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "metric",
      "text": "$1.2B Global Product Revenue",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69461611-5c51-40da-8e96-88d631ae406b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "metric",
      "text": ">6,000* Global VYVGART Patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc9f020a-b8c4-48f0-beef-48905e58b95e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.35,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~90% Access VYVGART after ≤2 Orals",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb2098e4-7511-4b91-a46d-2b8bf5525dd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* As of Q3 2023 Financial Results",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98ef7eef-10d2-41c0-9e7a-ca3bbd959307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Strong Commercial Execution in 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee25db08-ffc5-4c54-ad2b-f3e0752e6116",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 9,
      "beatId": "0d2c5fce-acef-4f51-b143-ee83c56196c4",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "The Breakthrough",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "Strong commercial execution and innovation builds autoimmune market opportunities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}